Detection of iga antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia

Abstract

Although human papillomavirus (HPV) is involved in the etiology of cervical carcinoma, there are no cervical carcinoma-specific HPV serologic tests available. We investigated the presence of broadly cross-reactive IgA antibodies to papillomavirus (PV) in cervico-vaginal secretions from patients with condylomata and cervical intraepithelial neoplasia (CIN). Purified bovine PV (BPV) virions were used as antigen in an enzyme-linked immunosorbent assay (ELISA). Forty-two women whose ages ranged from 20 to 50 participated in the study. Eight of 9 patients with CIN had IgA antibodies against PV in their cervical secretions. Three of 9 patients with koilocytosis and condylomas but no CIN had IgA antibodies to PV. Six of 24 women with normal Pap-smear and colposcopy also had IgA antibodies against PV in their cervical secretions. The proportion of IgA-positive cervical secretions was significantly higher in the CIN group than in the normal group (p less than 0.005). Our data suggest that IgA antibodies to PV may be a useful marker for CIN.

A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia.

“…The HPV capsid antigen is regularly immunogenic (5, 13) for both IgA and IgG antibodies (14) and is present in the outer layer of the infected epithelium (1, 13). In contrast, in the basal-cell layer HPV genomes can be demonstrated (1), but no viral antigen has been found (1,13 …”

“…The E2 gene encodes a transactivating factor (10), and an E2 protein has been detected on immunoblots of condylomas (11). Two of 72 condyloma patients had IgG antibodies against an E2-derived fusion protein (12).The HPV capsid antigen is regularly immunogenic (5, 13) for both IgA and IgG antibodies (14) and is present in the outer layer of the infected epithelium (1, 13). In contrast, in the basal-cell layer HPV genomes can be demonstrated (1), but no viral antigen has been found (1,13 …”

Comparison of ELISA and Western blotting for human papillomavirus type 16 E7 antibody determination

“…In the past few years increasing efforts have been made to develop serological tests capable of proving HPV infection. In these tests, three sources of antigens have been utilized: (i) intact or disrupted HPV virions extracted either from HPVinduced lesions (Pfister & zur Hausen, 1978;Baird, 1983;Dillner et al, 1989a;Steele & Gallimore, 1990;Anisimov/t et al, 1990) or from virus-infected xenografts in nude mice (Christensen & Kreider, 1990), (ii) genetically engineered HPV proteins, usually in the form of bacterial fusion proteins (Jenison et al, 1988(Jenison et al, , 1989Jochmus-Kudielka et al, 1989) or expressed as part of a capsid protein of genetically modified phage fd (Mfiller et al, 1990) and (iii) synthetic peptides derived from known sequences of different HPV DNA open reading frames (ORFs) (Cason et al, 1989;Dillner, 1990;Dillner et al, 1989bDillner et al, , 1990Such~.nkov/~ et al, 1990;Miiller et al, 1990).…”

Aspectos imunológicos da infecção pelo vírus do papiloma humano (HPV)

“…Estes anticorpos atuam contra frações antigênicas que são encontradas no muco cervical de pacientes com neoplasia cervical (DILLNER et al, 1989;DILLNER et al, 1993). Entretanto, ao contrário da resposta humoral do pulmão e intestino, há um predomínio de IgG ao invés da IgA no trato genital LYCKE, 2003).…”